Allucent Chairman and CEO Mark A. Goldberg Honored by PharmaVoice as One of the Year’s 100 Most Inspiring People in Life Sciences

Global biopharmaceutical services leader, Allucent, announced today that its Chairman and CEO, Mark A. Goldberg, M.D., has been named to the PharmaVoice 100 ‘Legacy Leaders’ category, recognizing him as one of the 100 most inspiring people in the life sciences industry for 2022.

Since 2005, PharmaVoice 100 has honored more than 1,700 industry leaders from across all sectors of the life sciences industry. According to PharmaVoice, this hallmark award is given to individuals who are a driving force in life sciences, in recognition of qualities and achievements including:

• An ability to view industry trends as opportunities not obstacles
• Passion and conviction for the industry
• Innovation and ability to think outside of the box and develop breakthrough strategies, products, and services
• Pioneering new paths for the industry and their companies
• Taking the time to mentor and guide the next generation of industry leaders
• Dedication to improving the lives of patients

“2022 has been a milestone year for Allucent, and personally, one of the most exciting and rewarding times in my career,” said Dr. Goldberg. “To see our company come together after a series of strategic acquisitions designed to address a market gap and serve the unique needs of small and mid-sized biotech companies, has been truly gratifying. Speaking on behalf of everyone at Allucent, we are honored for being recognized for what we have achieved together to date and for the opportunities that lie ahead.”

Currently, smaller companies hold approximately 70% of the biopharmaceutical industry’s intellectual property, and often benefit from third-party experts possessing clinical and regulatory experience and capabilities to ensure their innovations have the best chance of success. Allucent was purpose-built to address this need. With a series of acquisitions completed in the three years since Dr. Goldberg became CEO, most recently including clinical research provider Pharm-Olam in January of 2022, the company has doubled in size, strengthened and deepened its capabilities, and expanded its global reach. Allucent has built unique capabilities to serve the specialized needs of smaller biotech companies working to bring innovative new treatments to patients.